Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases

European Journal of Internal Medicine

Volumn 22, Issue 2, 2011, Pages 167-171

  Medina, Araceli Molina ^a   Marteles, Marta Sanchez ^b   Sáiz, Elisa Bermejo ^a   Martínez, Sandra Serrano ^a   Laiglesia, Fernando Ruiz ^b   Rodríguez, José A Nieto ^a   Pérez Calvo, Juan I ^b  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Chronic pulmonary diseases; Cor pulmonale; Natriuretic peptides; NT proBNP; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIURETIC AGENT;

ACUTE DISEASE; ADULT; AGED; ANAMNESIS; ARTICLE; ASTHMA; CAUSE OF DEATH; CHRONIC LUNG DISEASE; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEART ATRIUM FLUTTER; HEART FAILURE; HEART RHYTHM; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXYGEN THERAPY; PNEUMONIA; PREVALENCE; PROGNOSIS; RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PNEUMONIA; PREVALENCE; PROGNOSIS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 79952696620     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.12.002     Document Type: Article

References (25)

1. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203. (Pubitemid 24203680)
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with and without congestive heart failure: a substudy of the Studies of Left Ventricular Disfunction (SOLVD). Circulation 1990;82:1724-9. (Pubitemid 20367975)
3. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra T, Talmor D, et al. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007;131:964-71. (Pubitemid 46608693)
4. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-7. (Pubitemid 23171117)
5. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13. (Pubitemid 28020159)
6. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999;93:507-14. (Pubitemid 29364066)
7. Denus S, Pharand Ch, Williamson RD. Brain natriuretic peptide in management of heart failure. Chest 2004;125:652-68.
8. McCullough PA, Kuncheria J, Vandana S, Vandana S, Mortina B, Schindler C, Buser P, et al. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 2004;5:16-25. (Pubitemid 38344496)
9. Mueller C, Scoler A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54. (Pubitemid 38364623)
10. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30. (Pubitemid 30172933)
11. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63. (Pubitemid 38364624)
12. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7. (Pubitemid 34556391)
13. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30.
14. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. J Am Coll Cardiol 2002;16(39):202-9. (Pubitemid 34084622)
15. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:425-30.
16. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
17. Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008;264:166-76. (Pubitemid 351962572)
18. Bai M, Yang J, Li Y. Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation. Clin Cardiol 2009;32:E1-5.
19. Januzzi JL, Van Kimmenade RRJ, Lainchbury G, Bayes-Genis A, Pinton Y, Richards AM. Value of NT-proBNP for the evaluation of acute CHF: a multi-center, international pooled analysis of 1256 subjects: primary results from the International Collaborative of NT-proBNP (ICON) study. J Am Coll Cardiol 2005;45(Suppl A:140).
20. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF Study. J Card Fail 2009;15:377-84.
21. Gemici G, Erdim R, Celiker A, Tokay S, Ones T, Inanir S, et al. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther 2008;25:674-80.
22. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94. (Pubitemid 351685510)
23. Budweiser S, Luchner A, Jörres RA, Heinemann F, Hital AP, Schinidbauer K, et al. NT-proBNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis. Respir Med 2007;101:2003-10. (Pubitemid 47163527)
24. McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, et al. Baseline plasma NT-proBNP and clinical characteristics: results from the Irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010;16:128-34.
25. Ruttem FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-94. (Pubitemid 41253302)